Astrocytoma Segment Held Largest Share of Type Segment in Glioma Treatment Market

According to our latest study on " Glioma Treatment Market Size and Forecast to 2030 – COVID-19 Impact and Global Analysis – by Type, Treatment, Grade and End-Users," the market was valued at US$ 4,139.6 million in 2022 and is expected to reach US$ 8,292.5 million by 2030. It is estimated to witness a CAGR of 9.1% during 2022–2030. The report highlights the some of the key factors and trends impacting the target market and focuses on prominent players and their growth strategies.

Glioma is a tumor in the central nervous system, i.e. the brain and the spinal cord and is one of the most common types of primary brain tumors. It originates in the glial cell that surrounds and supports the nerve cells. It is characterized by the abnormal growth of brain cells and the spread of cancer to cells within the central nervous system. Gliomas affect brain function and may be life-threatening disease depending on their location and rate of growth. Glioma may occur in people of all ages but are more common in male adults.

The growing demand for better treatment modalities has resulted in various product developments in the last few decades. A few of the examples of recent product developments in the glioma treatment market are mentioned below.

•           In June 2023, F. Hoffmann-La Roche develops RG-6156 which is under clinical development and currently in Phase I for Glioblastoma Multiforme (GBM). EGFRvIII x CD3 (RG6156) is a T cell bispecific antibody that binds to EGFRvIII on tumor cells and CD3 on T cells. EGFRvIII is an activating EGFR mutation leading to increased tumorigenicity and is expressed in around 30% of glioblastoma (GBM)

•           In October 2022, Amneal launched first biosimilar with ALYMSYS (bevacizumab-maly) in the United States. ALYMSYS (bevacizumab-maly) in the U.S. is a type of vascular endothelial growth factor inhibitor suggested for the treatment of recurrent glioblastoma in the adults patients along with other cancer treatment.

•           In March 2020, the U.S. FDA Accepts Biologics License Application (BLA) for Mylan N.V and Biocon Limited Proposed Biosimilar Bevacizumab for Review. The BLA received approval of bevacizumab for first-line and second-line treatment option for the patients with metastatic colorectal cancer disease in combination with fluorouracil-based chemotherapy.

Based on end user, the market is segmented into hospitals & clinics, ambulatory surgical centers. In 2022, the hospitals & clinics segment held the leading share of the market. Moreover, hospitals & clinics segment is expected to grow at the fastest growth rate during the coming years. Hospitals serve as primary healthcare centers by employing qualified medical and healthcare personnel to offer convenient services and the best care to patients. Also, post-operative care is offered in the best possible manner to prevent further complications. As all the services are offered under one roof, hospitals are largely preferred across the world. Moreover, the availability of multiple hospitals in the countries allows patients to choose from different options for their treatments. majority of patients in emerging and developed countries prefer approaching hospitals to get treated for health-related problems. Further, the increasing number of hospitals, adoption of advanced diagnostic platforms, and growing accessibility of hospitals in developing nations would offer lucrative opportunities for the growth of the glioma treatment market for the hospitals segment during the forecast period.

F. Hoffmann-La Roche Ltd, Arbor Pharmaceuticals, LLC, Merck and Co., Inc., Sun Pharmaceutical Industries Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Amneal Pharmaceuticals, LLC., Bristol Mayers Squibb Company , Karyopharm Therapeutics, Inc., are among the prominent players in the global glioma treatment market.

The report segments the global glioma treatment market as follows:

The glioma treatment market is segmented based on type, treatment, grade, and end user. By type, the glioma treatment market is bifurcated into astrocytoma, oligoastrocytoma, and oligodendroglioma. By surgery, the glioma treatment market is bifurcated into surgery, chemotherapy, radiation therapy, and others

By grade, the glioma treatment market is bifurcated lower grade and high grade. The low grade is further bifurcated into Garde I and Grade II. The high grade is further bifurcated into Garde III and Garde IV. Based on end user, the glioma treatment market is segment into hospitals & clinics, ambulatory surgical centers. Geographically, the Glioma Treatment market is segmented into North America (the US, Mexico, and Canada), Europe (the UK, Spain, France, Germany, Italy, and the Rest of Europe), Asia Pacific (Japan, India, China, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa ( Saudi Arabia, the UAE, South Africa and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com